BACKGROUND AND OBJECTIVES: Patients with in-transit melanoma metastasis have longer median survival than patients with distant metastatic disease. Furthermore, local disease control is an important endpoint for symptom management. The treatment of unresectable loco-regional recurrence or in-transit disease has been historically managed with a combination of treatments including surgery, radiotherapy, isolated limb infusion or perfusion as well as systemic therapies. Intralesional PV-10 has been used at Peter MacCallum Cancer Centre since 2010, and the current report presents a retrospective analysis of patient outcomes, reporting the response rates, durability of responses, and observed toxicities. METHODS: Records were analyzed retrieving details of 19 patients treated with PV-10 over a 4-year period from 2010 to 2014. Medical records were reviewed for these patients and data extracted. RESULTS: Nineteen patients with in-transit melanoma were treated with intralesional PV-10 between 2010 and 2014. Disease control (complete or partial response or disease stability) was achieved in 68% of patients with 26% having a complete response. This was achieved with minimal associated toxicity. CONCLUSIONS: PV-10 is an effective, durable, well-tolerated treatment tool with an acceptable side effect profile for the management of unresectable in-transit melanoma. J. Surg. Oncol. 2016;114:380-384.
BACKGROUND AND OBJECTIVES:Patients with in-transit melanoma metastasis have longer median survival than patients with distant metastatic disease. Furthermore, local disease control is an important endpoint for symptom management. The treatment of unresectable loco-regional recurrence or in-transit disease has been historically managed with a combination of treatments including surgery, radiotherapy, isolated limb infusion or perfusion as well as systemic therapies. Intralesional PV-10 has been used at Peter MacCallum Cancer Centre since 2010, and the current report presents a retrospective analysis of patient outcomes, reporting the response rates, durability of responses, and observed toxicities. METHODS: Records were analyzed retrieving details of 19 patients treated with PV-10 over a 4-year period from 2010 to 2014. Medical records were reviewed for these patients and data extracted. RESULTS: Nineteen patients with in-transit melanoma were treated with intralesional PV-10 between 2010 and 2014. Disease control (complete or partial response or disease stability) was achieved in 68% of patients with 26% having a complete response. This was achieved with minimal associated toxicity. CONCLUSIONS:PV-10 is an effective, durable, well-tolerated treatment tool with an acceptable side effect profile for the management of unresectable in-transit melanoma. J. Surg. Oncol. 2016;114:380-384.
Authors: Brittany L Bunch; Krithika N Kodumudi; Ellen Scott; Jennifer Morse; Amy Mackay Weber; Anders E Berglund; Shari Pilon-Thomas; Joseph Markowitz Journal: Cancer Immunol Immunother Date: 2020-06-18 Impact factor: 6.968
Authors: Xiang Wen; Xiaoshen Zhang; Grzegorz Szewczyk; Ahmed El-Hussein; Ying-Ying Huang; Tadeusz Sarna; Michael R Hamblin Journal: Antimicrob Agents Chemother Date: 2017-06-27 Impact factor: 5.191
Authors: Tavis A Read; Aaron Smith; Janine Thomas; Michael David; Matthew Foote; Michael Wagels; Andrew Barbour; B Mark Smithers Journal: J Surg Oncol Date: 2018-03-12 Impact factor: 3.454
Authors: Corina Behrenbruch; Carolyn Shembrey; Sophie Paquet-Fifield; Christina Mølck; Hyun-Jung Cho; Michael Michael; Benjamin N J Thomson; Alexander G Heriot; Frédéric Hollande Journal: Clin Exp Metastasis Date: 2018-01-15 Impact factor: 4.510